L
Labiana Health SA
MAD:LAB
Labiana Health SA
MAD:LAB
Price:
4.66
EUR
-2.1%
Market Cap:
€39.6m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
L
|
Labiana Health SA
MAD:LAB
|
ES |
|
Lynch Group Holdings Ltd
ASX:LGL
|
AU |
Multiples-Based Value
The Multiples-Based Value of one LAB stock under the Base Case scenario is 7.65 EUR. Compared to the current market price of 4.66 EUR, Labiana Health SA is Undervalued by 39%.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
LAB
Multiples-Based Value
Base Case
7.65
EUR
Undervaluation 39%
L
Multiples Across Competitors
LAB Competitors Multiples
Labiana Health SA Competitors
Labiana Health SA Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| ES |
L
|
Labiana Health SA
MAD:LAB
|
39.6m EUR | 0.6 | 43.7 | 3.5 | 5.6 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
887.6B USD | 13.6 | 43 | 29 | 31 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
574.2B USD | 6.1 | 21.4 | 14.9 | 18.3 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
236.2B GBP | 5.3 | 30.3 | 16.8 | 23.6 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 4.1 | 19.5 | 11.6 | 13 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
300.5B USD | 4.6 | 16.5 | 10.2 | 12.4 | |
| CH |
|
Novartis AG
SIX:NOVN
|
233.6B CHF | 5.2 | 20.8 | 12.9 | 16.6 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 105.4 | -83.6 | 386.8 | 970 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 3.4 | 10.3 | 7.6 | 8.9 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
153.1B USD | 2.4 | 19.7 | 7.6 | 10.1 | |
| UK |
|
GlaxoSmithKline PLC
LSE:GSK
|
88.7B GBP | 2.7 | 15.5 | 8.4 | 10.4 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
